A Drug-Drug Interaction Study of Diltiazem and MK-1167 in Healthy Adult Participants (MK-1167-006)

Phase 1

Completed

Brief Summary: The goal of this study this study is to learn about the safety of MK-1167 and if people tolerate it. Researchers will compare what happens to MK-1167 in the body when it is given with and without another medicine called diltiazem.

Recruitment & Eligibility

Inclusion Criteria

The main inclusion criteria include but are not limited to the following:

Continuous non-smoker who has not used nicotine- and tobacco-containing products for at least 3 months prior to the first dosing based on participant self-reporting
Body mass index (BMI) ≥18.0 and ≤32.0 kg/m^2
Able to swallow multiple capsules
In good health

Exclusion Criteria

The main exclusion criteria include but are not limited to the following:

History or presence of second- or third-degree atrioventricular heart block (except in participants with a functional artificial pacemaker)
History or presence of clinically significant sick sinus syndrome
History of cancer (malignancy) within the past 5 years
Unable to refrain from or anticipates the use of any drugs, including prescription and non-prescription medications, herbal remedies, or vitamin supplements beginning 14 days prior to the first dosing

Arm && Interventions

Group	Intervention	Description
MK-1167 Period 1	MK-1167	On Day 1 a single dose of MK-1167 will be administered.
MK-1167 Period 2	MK-1167	There will be a washout of at least 35 days between MK-1167 dosing in Period 1 and the first diltiazem dose in Period 2. In Period 2, diltiazem will be administered once daily (QD) for 49 consecutive days with a single dose of MK-1167 coadministered on Day 3.
MK-1167 Period 2	Diltiazem	There will be a washout of at least 35 days between MK-1167 dosing in Period 1 and the first diltiazem dose in Period 2. In Period 2, diltiazem will be administered once daily (QD) for 49 consecutive days with a single dose of MK-1167 coadministered on Day 3.

Primary Outcome Measures

Name	Time	Method
Number of participants who experience one or more adverse events (AEs)	Up to approximately 99 days	An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.
Number of participants who discontinue study intervention due to an AE	Up to approximately 85 days	An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.
Area under the concentration versus time curve from 0 to infinity after single dosing (AUC0-inf) of MK-1167 in plasma	Predose, and at designated timepoints up to 50 days post-dose	AUC0-inf of MK-1167 in plasma will be determined.

Secondary Outcome Measures

Name	Time	Method
Area under the concentration versus time curve from 0 to last quantifiable sample (AUC0-last) of MK-1167 in plasma	Predose, and at designated timepoints up to 50 days post-dose	AUC0-last of MK-1167 in plasma will be determined.
Maximum concentration (Cmax) of MK-1167 in plasma	Predose, and at designated timepoints up to 50 days post-dose	Cmax of MK-1167 in plasma will be determined.
Concentration at hour 24 (C24) of MK-1167 in plasma	Predose, and at designated timepoints up to 24 hours post-dose	C24 of MK-1167 in plasma will be determined.
Time to maximum concentration (Tmax) of MK-1167 in plasma	Predose, and at designated timepoints up to 50 days post-dose	Tmax of MK-1167 in plasma will be determined.
Apparent terminal half-life (t1/2) of MK-1167 in plasma	Predose, and at designated timepoints up to 50 days post-dose	t1/2 of MK-1167 in plasma will be determined.
Apparent clearance (CL/F) of MK-1167 in plasma	Predose, and at designated timepoints up to 50 days post-dose	CL/F of MK-1167 in plasma will be determined.
Apparent volume of distribution during terminal phase (Vz/F) of MK-1167 in plasma	Predose, and at designated timepoints up to 50 days post-dose	Vz/F of MK-1167 in plasma will be determined.